Wave Life Sciences Ltd.
General ticker "WVE" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.5B (TTM average)
Wave Life Sciences Ltd. follows the US Stock Market performance with the rate: 10.5%.
Estimated limits based on current volatility of 3.6%: low 7.07$, high 7.60$
Factors to consider:
- Total employees count: 288 as of 2024
- Top business risk factors: Insufficient funding, Economic downturns and volatility, Labor/talent shortage/retention, Pandemic risks, Cybersecurity threats
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.37$, 18.30$]
- 2025-12-31 to 2026-12-31 estimated range: [5.13$, 13.19$]
Financial Metrics affecting the WVE estimates:
- Negative: with PPE of -16.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.37 <= 0.33
- Negative: negative Net income
- Positive: 41.86 < Shareholder equity ratio, % of 59.49 <= 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of -0.05 > -0.66
Short-term WVE quotes
Long-term WVE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3.65MM | $113.31MM | $108.30MM |
| Operating Expenses | $166.37MM | $181.30MM | $218.71MM |
| Operating Income | $-162.72MM | $-68.00MM | $-110.40MM |
| Non-Operating Income | $1.58MM | $9.81MM | $13.39MM |
| R&D Expense | $115.86MM | $130.01MM | $159.68MM |
| Income(Loss) | $-161.14MM | $-58.19MM | $-97.01MM |
| Taxes | $0.68MM | $-0.68MM | $0.00MM |
| Profit(Loss)* | $-161.82MM | $-57.51MM | $-97.01MM |
| Stockholders Equity | $-45.09MM | $39.63MM | $209.51MM |
| Assets | $146.39MM | $274.95MM | $352.21MM |
| Operating Cash Flow | $-127.78MM | $-19.43MM | $-151.03MM |
| Capital expenditure | $1.36MM | $1.11MM | $0.94MM |
| Investing Cash Flow | $-1.25MM | $-1.11MM | $-0.94MM |
| Financing Cash Flow | $67.19MM | $132.53MM | $253.89MM |
| Earnings Per Share** | $-2.05 | $-0.54 | $-0.70 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.